How do I buy Grifols, S.A. American Depositary Shares (GRFS) stock?

Buying Grifols, S.A. American Depositary Shares (GRFS) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "GRFS", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy GRFS by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for GRFS on Gotrade?

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Grifols, S.A. American Depositary Shares from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Grifols, S.A. American Depositary Shares (GRFS) pay dividends?

Yes, Grifols, S.A. American Depositary Shares regularly pays dividends to shareholders. Currently, the estimated dividend yield for GRFS is around 1.04% per year. On Gotrade, cash dividends will be automatically credited to your account balance (after taxes).

Is buying GRFS on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy GRFS?

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours. Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

How do I tell if GRFS is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Grifols, S.A. American Depositary Shares (GRFS) Stock Price Today & Analysis

% positive news of 10 articles

published over the past 14 days

Latest news

Zacks Investment Research

About Grifols, S.A. American Depositary Shares

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

SectorHealthcare

IndustryDrug Manufacturers - General

Employees25,258

CEOMr. Jose Ignacio Abia Buenache

IPO DateMay 17, 2006

HeadquartersBarcelona, Spain

Key Executives

Name	Title	Year Born
Mr. Jose Ignacio Abia Buenache	CEO & Director	1968
Mr. Rahul Srinivasan	Chief Financial Officer	1977
Mr. Lluis Pons Gomez	Senior Vice President of Strategy & COO Office	1984
Daniel Segarra	Head of Investor Relations & Sustainability and Vice President	—
Mr. David Ian Bell	Chief Corporate Affairs & Legal Officer	1954
Mr. Enrique de la Torre	Chief Compliance Officer	1973
Ms. Montse Ribas	Chief Communications and Reputation Officer	1969
Mr. Camille Alpi	Chief Human Resources & Talent Officer	1981
Mr. Vicente Blanquer Torre	Chief Quality Officer	1961
Mr. Ignacio Ramal Subira	Chief Internal Audit & Enterprise Risk Manager	1968

Fundamentals

Valuation

Market cap$5.00B

Price-to-sales ratio0.56

Price-to-book value0.80

Price-earnings ratio10.60

Return on EquityN/A

Return on SalesN/A

Return on AssetsN/A

PEG ratio0.23

Earnings Per Share

Earnings Per Share$0.69

Income Statement

Average volume586,102

EBITDA$1.87B

1 year high (52w)$10.23

1 year low (52w)$6.96

Dividend

Ex dividend date2 Jul 2026

Dividend amount$0.17

Dividend yield1.04%

Last payment date9 Jul 2026

Dividend yield (TTM)1.21%

Next earnings reportN/A

Solvency

Debt-to-equity ratioN/A

Technicals

OscillatorsStrong Sell5 Indicators

Moving AveragesStrong Sell12 Indicators

What the experts say

0 Wall Street Analyst Ratings

N/A

0% Buy

0% Hold

0% Sell

Target price

$0.00

Est return

0.00%

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026		+0.3	-11.8	-0.1	-4.6	-8.5	+11.2	-1.8	-4.9

Corporate actions

Upcoming

No upcoming corporate actions for GRFS

Past

DividendQ3/26

Ex-dividend date2 Jul 2026

Payable date9 Jul 2026

Amount per share$0.09

Grifols, S.A. American Depositary Shares (GRFS) Stock

Fundamentals

Recent news

GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?

GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?

Grifols says Canada plasma license suspension has no impact

Grifols says Canada plasma license suspension has no impact

GRFS or SDZNY: Which Is the Better Value Stock Right Now?

GRFS or SDZNY: Which Is the Better Value Stock Right Now?

Grifols Q2 Earnings Call Highlights

Grifols Q2 Earnings Call Highlights

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?

GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?

Grifols says Canada plasma license suspension has no impact

Grifols says Canada plasma license suspension has no impact

GRFS or SDZNY: Which Is the Better Value Stock Right Now?

GRFS or SDZNY: Which Is the Better Value Stock Right Now?

Grifols Q2 Earnings Call Highlights

Grifols Q2 Earnings Call Highlights

Grifols approves IPO of its US biopharma business

Grifols approves IPO of its US biopharma business

Grifols doubles net profit in 2025, driven by revenues

Grifols doubles net profit in 2025, driven by revenues

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

New Strong Sell Stocks for July 31st

New Strong Sell Stocks for July 31st

GRFS or ZTS: Which Is the Better Value Stock Right Now?

GRFS or ZTS: Which Is the Better Value Stock Right Now?

GRFS or ZTS: Which Is the Better Value Stock Right Now?

GRFS or ZTS: Which Is the Better Value Stock Right Now?

About Grifols, S.A. American Depositary Shares

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

Corporate actions

Upcoming

Past

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade